Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases

CorMedix secures FDA Priority Review for REZZAYO prophylaxis, with decision expected Q1 2027.

What the company is saying

CorMedix Therapeutics is announcing that the FDA has accepted for filing its supplemental New Drug Application (sNDA) for REZZAYO (rezafungin for injection) for the prophylaxis of invasive fungal disease, submitted by its global partner Mundipharma. The company highlights that the FDA has granted Priority Review, setting a Prescription Drug User Fee Act (PDUFA) target action date in Q1 2027, and frames this as a significant regulatory milestone. CorMedix emphasizes the positive topline results from the Phase III ReSPECT pivotal study, which compared once-weekly rezafungin to a standard antimicrobial regimen in adults undergoing allogeneic HSCT. CEO Joseph Todisco is quoted to reinforce the importance of this milestone for patients at risk and the company's future plans. The company states that, if approved, it aims to begin promotional activities in the second half of 2027. The announcement also details REZZAYO’s current FDA approval for candidemia and invasive candidiasis in adults and pediatric patients 12 years or older with limited or no alternative options, and notes orphan drug exclusivity through 2035 and patent protection through 2038 in the U.S. Safety information, including the most common adverse reactions (≥5%) and contraindications, is disclosed, with warnings about hypersensitivity, infusion reactions, photosensitivity, and hepatic adverse events.

What the data suggests

The FDA’s acceptance of the sNDA for REZZAYO and granting of Priority Review with a Q1 2027 PDUFA date are confirmed regulatory milestones, not guarantees of approval. The application is supported by positive topline results from the Phase III ReSPECT study, but no detailed efficacy or safety data are disclosed in this announcement. REZZAYO is already FDA-approved for candidemia and invasive candidiasis in patients 12 years or older with limited options, but is not yet approved for prophylaxis of invasive fungal disease; its safety and efficacy for this use remain unestablished. The company reports that mortality rates for invasive candidiasis can reach 40%, underscoring the unmet need. Orphan drug exclusivity through 2035 and patent coverage through 2038 provide a long runway for potential market protection if the new indication is approved. The most common adverse reactions have an incidence of at least 5%, and include hypokalemia, pyrexia, diarrhea, anemia, vomiting, nausea, hypomagnesemia, abdominal pain, constipation, and hypophosphatemia. There is no financial data, sales guidance, or commercial projections in this release. The evidence presented is strictly regulatory and clinical-stage, with all commercial impact contingent on future FDA approval.

Analysis

The announcement is primarily factual, reporting the FDA's acceptance of the sNDA for REZZAYO and the granting of Priority Review status, both of which are realised regulatory milestones. The only forward-looking claim is the intention to begin promotional efforts in the second half of 2027 if approval is granted, which is appropriately caveated. There is no evidence of exaggerated language or narrative inflation; the tone is positive but proportionate to the regulatory progress disclosed. No large capital outlay or immediate financial impact is mentioned, and the announcement does not overstate the certainty of future commercial success. The absence of financial or profitability metrics is not a deficiency here, as this is a regulatory update typical for a biotech at this stage. The data supports a weak_positive signal due to the achievement of a key milestone, but the benefits are long-term and contingent on future FDA approval.

Risk flags

• ●Regulatory approval risk is high: FDA acceptance and Priority Review do not guarantee approval, and the agency may request additional data, extend review, or approve with narrower labeling than requested. This matters because commercial launch and revenue are entirely contingent on a positive FDA decision.
• ●Clinical risk persists: While positive topline results from the Phase III ReSPECT study are cited, the full data set and detailed efficacy or safety outcomes are not disclosed here, leaving uncertainty about the strength and generalizability of the clinical evidence.
• ●Commercial timing risk is present: Even if approval is granted, CorMedix does not plan to begin promotional efforts until the second half of 2027, meaning any revenue impact is at least several quarters away. Delays in approval or launch preparation could further push out commercial realization.
• ●Safety and adverse event risk: The most common adverse reactions have an incidence of at least 5%, and include serious conditions such as hypokalemia and anemia, which could affect uptake or labeling if safety signals emerge during review or post-market surveillance.

Bottom line

CorMedix has achieved a key regulatory milestone with FDA acceptance and Priority Review of its sNDA for REZZAYO as prophylaxis for invasive fungal disease, with a decision expected in Q1 2027. The announcement is strictly regulatory and clinical, with no financial projections or commercial agreements disclosed, and all future revenue from this indication remains contingent on FDA approval. The company’s messaging is measured, caveating that approval is not assured and commercial launch would not begin before the second half of 2027. Investors should recognize that while orphan drug exclusivity and patent protection could provide long-term market advantages, the immediate investment case hinges on the outcome of the FDA review and subsequent execution of a successful launch. The most important takeaway is that this is a necessary but early step toward commercial expansion, with material value realization still dependent on regulatory and operational execution.

Announcement summary

(NASDAQ:CRMD) CorMedix Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for REZZAYO® (rezafungin for injection) for the prophylaxis of invasive fungal disease. The sNDA was submitted by Mundipharma, CorMedix’s global development partner, and the FDA has granted Priority Review status with a Prescription Drug User Fee Act (PDUFA) target action date in Q1 2027. The sNDA is supported by the Phase III ReSPECT pivotal study, which evaluated the efficacy and safety of once weekly rezafungin compared with a standard antimicrobial regimen for prophylaxis in adults undergoing allogeneic hematopoietic stem cell transplantation (HSCT). CorMedix announced positive topline results from the ReSPECT study in April. If REZZAYO is approved for this new indication, CorMedix is targeting to begin promotional efforts in the second half of 2027. Joseph Todisco, Chairman & Chief Executive Officer of CorMedix, stated that the FDA’s acceptance of the supplemental application for Priority Review is an important regulatory milestone for CorMedix, REZZAYO, and patients at risk for invasive fungal disease. REZZAYO is currently approved by the FDA for the treatment of candidemia and invasive candidiasis in adults and pediatric patients 12 years of age or older who have limited or no alternative options for treatment. Mortality rates for patients with invasive candidiasis have been reported to be as high as 40%. Rezafungin has orphan drug exclusivity through 2035 and patent coverage through 2038 in the United States. REZZAYO is not approved by the FDA for the prophylaxis of invasive fungal diseases, and its safety and efficacy for that use have not been established. The most common adverse reactions (incidence ≥ 5%) are hypokalemia, pyrexia, diarrhea, anemia, vomiting, nausea, hypomagnesemia, abdominal pain, constipation, and hypophosphatemia. REZZAYO is contraindicated in patients with known hypersensitivity to rezafungin or other echinocandins. Warnings include the risk of hypersensitivity reactions, including anaphylaxis, infusion-related reactions, photosensitivity, and hepatic adverse reactions. REZZAYO is a registered trademark of Mundipharma, used under license by Melinta Therapeutics LLC, a wholly owned subsidiary of CorMedix Inc. in the US.

Disagree with this article?